1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML_GT60_DD, NCT00180167
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LAP-R2007, NCT00504764
|
|
7.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 30052004, NCT00196768
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
|
|
10.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AMLSG07-04, NCT00151242
|
|
12.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: Levosta-CBF-02/04, NCT00215007
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 35 and under
Sponsor: Other
Protocol IDs: 0005M52481, MT2000-12, 2000LS040, NCT00176839
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: EudraCT:2005-000805-68, NCT00354120
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: 012000, NCT00382759
|
|
16.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0358, NCT00398983
|
|
17.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
18.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
19.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
20.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: EORTC-06991, NCT00004128, GIMEMA-EORTC-06991
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI
Protocol IDs: SWOG-S0106, S0106, NCT00085709
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2902, E2902, NCT00093470
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AML_CR2_allo_HSCT, NCT00125606
|
